The 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines recommend two antifibrotic agents for the treatment of IPF: nintedanib and pirfenidone. Although neither is curative, studies have demonstrated that both can slow the fibrotic changes associated with IPF, which preserves lung function and reduces the risk for acute exacerbations.
Radiation and chemotherapy are typically not recommended for the management of IPF.
Support groups may be helpful for patients with IPF, but this is not a reason for the importance of establishing an early diagnosis.
Learn more about antifibrotic agents for IPF.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Guy W. Soo Hoo, Zab Mosenifar. Fast Five Quiz: Idiopathic Pulmonary Fibrosis Differential Diagnosis - Medscape - Jan 26, 2023.
Comments